Drew Armstrong
Bloomberg News

Alere Inc.’s former chief executive officer is working with shareholders to buy the health-services company and take it private for $46 a share.

Ron Zwanziger, who served as Alere’s CEO until July, is one of the Waltham, Massachusetts-based company’s biggest stockholders and has been contacting investors and at least one fellow former executive about a possible takeover for the last two months, according to a filing today. The shares surged the most in almost 14 months.

“Such a transaction is financeable at a price of $46 per share or perhaps higher, depending on the results of due diligence,” Zwanziger said in the filing. “The Former Officers believe that the Issuer’s common stock is undervalued in the market and that the Proposed Transaction will create and deliver a substantial increase in shareholder value.”

Zwanziger’s $46-a-share offer values the company at $3.82 billion, 25 percent above the stock’s closing price Sept. 12.

Alere rose 14 percent to $41.56 at 10:02 a.m. New York time, after climbing to $43 in their biggest intraday increase since July 31, 2013.

Jackie Lustig, a spokeswoman for Alere, said the company had no comment.

Zwanziger resigned from Alere after losing his role as chairman of the board in May. The company said after Zwanziger’s resignation that the board would conduct a strategic review.

Alere makes diagnostics, including a test for the HIV virus. The company had sales of $3.03 billion last year.